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Introduction
Mitral regurgitation is the most common valvular heart
condition in industrialized countries.1
This condition could result from structural abnormal-
ities, affecting the valvular leaflets or the subvalvular
apparatus (primary mitral incompetence, either organ-
ic, or degenerative), or be secondary to left ven-
tricular (LV) remodeling (secondary or functional
mitral incompetence).
The most common cause of organic mitral regurgitation
in Western countries is degenerative disease, further
subdivided intomyxomatousdegeneration (more frequent
in younger population), and fibroelastic degeneration
(more common in the elderly).2
Other causes include rheumatic disease (sharply declin-
ing in the Western countries), infective endocarditis,
traumatic chordae rupture, congenital malformations,
and annular calcification commonly found in the elderly.3
Functional mitral incompetence is the consequence of
LV remodeling (ischemic or idiopathic cardiomyopathy)
without structural anomalies of the valvular apparatus.
Medical treatment offers limited advantages in severe
organic mitral regurgitation, whether surgical treatment
represents the first choice option.4,5
The advantages in terms of perioperative mortality and
long-term survival have been firmly documented in
favor of surgical repair compared with valve replace-
ment.
Surgical mitral valve repair, when carried out before the
occurrence of LV dysfunction, can provide patients youn-
ger than 65 years with a standard surgical risk, with a life
expectancy similar to the general population.6
For isolated functional mitral regurgitation, in which the
prognosis is dependent more on the underlying myo-
cardial condition than on the mitral regurgitation per se,
medical therapy with angiotensin converting enzyme-
inhibitors, beta-blockers and aldosterone-antagonists
provides symptoms relief and prolongs survival, whether
the results of surgery are suboptimal, and with nonne-
gligible perioperative mortality.7–9 Furthermore, albeit
an improvement in symptoms and in quality of life has
been demonstrated after surgery,10 this result is not
followed by a better survival as compared with medical
treatment.11
The surgical treatment of isolated functional mitral
regurgitation (without myocardial revascularization)
received a level IIb recommendation in the Guidelines,5
to emphasize the scarcity of data and evidences in this
situation. Many of these patients are denied surgery
because of the overwhelming comorbidities.12
In patients older than 70 years, whose treatment should be
directedmore at improving the quality than thequantity of
life, a less invasive procedure could be referable.
During the last decade, technological advances provided
more advanced open surgical techniques (via sternotomy
or mini-thoracotomy), and percutaneous repair.
The development of percutaneous techniques has been
driven by need for less invasive approach vis-a`-vis the
impact of comorbidity affecting patients with mitral
regurgitation, often presenting with a prohibitive surgical
risk.
Surgical repair
Degenerative mitral regurgitation
Treating patients with organic mitral regurgitation
requires a precise understanding of the pathophysiology
and the natural history of the condition, as well as a
careful consideration of the efficacy and the timing of
the treatment.
According to American Heart Association/American
College of Cardiology4 and the European Society of
Cardiology/European Association for Cardio-Thoracic
Surgery,5 the decision for surgery should take into con-
sideration: the presence of symptoms, the LV ejection
fraction, the LV tele-diastolic volume, the presence of
pulmonary hypertension, atrial fibrillation, and the feasi-
bility of the surgical repair. Observational studies suggest
that the best results for surgical correction of severemitral
regurgitation are achieved when surgery is carried out in a
timely fashion, before the onset of symptoms and before
the pathophysiologic consequences of mitral regurgi-
tation take hold.13
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Patients with mitral regurgitation progressively develop
irreversible depression of myocardial contractility, sec-
ondary to volume overload. When this situation ensues
surgery improves symptoms, but not long-term survival.14
Whenever possible, surgical repair should be preferred
over valve replacement, because of better long-term
survival.15
The specific surgical technique is a function of the lesion
detected and assessed both preoperatively and intra-
operatively, and could involve the leaflets, the subvalv-
ular apparatus, and the annulus.
The results of surgical repair are excellent, also for very
complexmitral lesions, in younger patients with few or no
comorbidities. After surgery, these patients enjoy a qual-
ity of life and a survival similar to the general population,
with a low incidence of redo operations, thromboembolic
and cardiac events, and a significant and stable reduction
of the mitral regurgitation in time.16
Excellent results are achieved also for elderly, but other-
wise healthy patients, but become suboptimal for older
(>70 years) patients, with significant comorbidities. In
these patients, mortality is high and the quality of life not
improved. The available data suggest that the presence of
comorbidities plays a significant role in the success of
surgical treatment.17
Functional mitral regurgitation
The prognosis of patients with functional mitral regurgi-
tation is strictly related to the underlying cardiomyopathy.
Isolated mitral valve repair, which is not associated with
coronary artery bypass surgery, improves patients’ symp-
toms, but not survival (evidence Class IIb). It has been
shown that combination of coronary artery bypass surgery
and mitral valve repair is more effective than coronary
artery bypass alone in reducing the degree of mitral
regurgitation.4,5 On the other hand, the definitive benefit
of the combined procedure remains to be proven.
Several observational studies failed to prove a substantial
advantage in terms of symptomatic improvement and
survival comparing coronary bypass alone versus com-
bined bypass and mitral valve repair.
Randomized trials suggested that after 1 or 2 years of
follow-up, moderate or severe mitral regurgitation was
less common in patients after a combined procedure, but
the same patients had a longer hospital stay and a higher
number of neurologic events and supraventricular
arrhythmias. Conversely, other observational studies
and small randomized trials showed a similar mortality
for the two groups of patients, but the clinical status and
the functional class (NYHA class) of patients after com-
bined procedure were better.10
The vast majority of these procedures include an
undersized annuloplasty.
A recent randomized trial published on the New England
Journal of Medicine demonstrated that for patients
with functional mitral incompetence, there were no dif-
ferences in terms of inverse remodeling and 2-year
survival.18
Accordingly, surgical treatment is still under debate.19
Surgery should not be considered for patients with
advanced right ventricular dysfunction, absence of pre-
load reserve, and when severe comorbidities are present.
Surgery could be recommended, with acceptable mor-
bidity and mortality, for selected patients after careful
assessment of the risk of surgery, the clinical history, and
the severity of the LV remodeling process. In these
carefully selected patients, small studies demonstrated,
apart from a symptomatic and quality-of-life improve-
ment, a reverse cardiac remodeling.3
Percutaneous treatment with the MitraClip
system
Percutaneous mitral valve repair is a therapeutic option
when surgical repair is not feasible for excessive comor-
bidities, advanced age, or severe LV dysfunction.
Degenerative and functional mitral regurgitation
According to the 2012 European Guidelines,5 the edge-
to-edge percutaneous procedure could be considered for
patients with severe degenerative mitral regurgitation,
who qualify according to the echocardiographic eligibility
criteria, and who are not candidates or are at too high a
risk for surgery as determined by a Heart Team, and who
have a life expectancy longer than 1 year (Class IIb, level
of evidence C). The same recommendation is given for
patients with secondary severe mitral regurgitation,
despite optimal medical therapy, who are not candidates
for surgery as assessed by the Heart Team, and who have
at least 1-year life expectancy (Class IIb, level of evi-
dence C).
The EVEREST I study,20 the first MitraClip (Vascular,
Illinois, USA) feasibility study whose population mostly
included patients with structural mitral regurgitation,
demonstrated that the MitraClip procedure is well toler-
ated and effective with an encouraging feasibility rate.
The EVEREST II study, a prospective randomized trial
comparing the MitraClip procedure versus surgical
repair, showed that although percutaneous repair was
less effective at reducing mitral regurgitation than con-
ventional surgery, the procedure was associated with
superior safety and similar improvements in clinical out-
comes. The better control of mitral regurgitation offered
by surgery was not maintained after a 5-year follow-up.20
It is important to notice that patients enrolled in the
EVEREST studies were significantly different from
patients encountered in today’s real-world MitraClip
practice: at present, patients receiving the MitraClip
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are mostly affected with functional mitral regurgitation,
are older, and not suitable or at too high risk for surgery, as
determined by a Heart Team. Furthermore, the learning
curve for the percutaneous procedure could have affected
the results.
An important contribution to the understanding of the
problem has been provided by the analysis of observa-
tional registries and the high-risk subgroups of the
EVEREST studies.
The ACCESS-EU21 registry is the most representative of
the real-world characteristics of patients undergoing the
MitraClip procedure: advanced age, many comorbidities,
high surgical risk, and with functional mitral regurgitation.
The results of the TRAMI22 registry, one of the largest
published, confirmed the MitraClip procedure as a valid
therapeutic option for high surgical risk patients. Further
important considerations can be derived by the GRASP23
registry which included patients undergoing the Mitra-
Clip procedure with moderate-severe and severe organic
(24%) and functional (76%) mitral incompetence, pro-
posed for standard surgical repair, but judged by the
Heart Team to be at high surgical risk on the basis of
comorbidities, LV dysfunction, and Logistic Euro-Score.
The immediate procedural success, defined as the
stable implant of one or more MitraClips with reduction
to a moderate or low-degree mitral regurgitation, was
achieved in all patients; the cumulative mortality at
30 days and 12 months was 0.9 and 14%, respectively,
with more than half of noncardiovascular-related deaths.
Based on all these studies, the conclusion is that the
MitraClip procedure is well tolerated and effective and
can be recommended as a valid alternative to surgery in
high-risk or inoperable patients.
The limitation of the EVEREST studies, on the other
hand, is the limited number of patients and the lack of a
control group; the ongoing American study COAPT,
comparing MitraClip with optimal medical therapy in
patients with functional mitral regurgitation, should pro-
vide some of these answers.
Conclusion
Currently, the ideal candidates for surgical repair of mitral
regurgitation are patients at low surgical risk, during the
initial stages of the disease, with a recent history of heart
failure and limited LV dilation. On the contrary, most of
the patients present for treatment with advanced stages
of the disease.
The percutaneousMitraClip procedure represents a valid
alternative to surgery, particularly in older patients with
decreased LV function and important comorbidities.
Currently, around the world, more than 40 000 patients
received MitraClip treatment with excellent periopera-
tive and follow-up morbidity and mortality. The future
challenge is reaching similar results in the permanent
reduction of mitral incompetence, thus allowing the
procedure to be offered to lower surgical risk patients.
Today percutaneous techniques are becoming available,
such as percutaneous annuloplasty, potentially capable
of improving the functional results of these procedures,
thus approaching the results of standard surgical tech-
niques. To this end, the role of an expert Heart Team
(cardiologist and cardiac surgeons) is paramount in offer-
ing the patient an individualized therapeutic approach,
which takes into account his/her clinical conditions, the
characteristics of the valvular and subvalvular structures,
and the extent of the underlying cardiomyopathy.
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